StockSelector.com
  Research, Select, & Monitor Saturday, September 22, 2018 5:04:43 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Revance Therapeutics, Inc.$25.10$.753.08%

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Revance Therapeutics, Inc. has an overall rank of 7097 out of 7243 stocks based on 4 positive rankings and 10 negative rankings.

Positive Rankings
Estimated Revenue Growth
Revance Therapeutics rank is 54
Debt-to-Equity
Revance Therapeutics rank is 173
Low/Rising MACD
The MACD remains negative, but is rising... suggesting a possible near-term correction. Of companies with a negative, but rising MACD, Revance Therapeutics is ranked 225.
Highest Cash Growth
Revance Therapeutics rank is 326
Negative Rankings
Price-to-Sales
Revance Therapeutics rank is 29
Negative Net Margin
Revance Therapeutics rank is 31
Down EPS Surprise
Revance Therapeutics missed the consensus earnings estimate when it last reported quarterly earnings.
Negative Revenue Growth
Revance Therapeutics rank is 180
Down Ratings Revision
During the past month, the average analyst's rating or recommendation has decreased. Among companies that have been downgraded within the past month, Revance Therapeutics is ranked 199.
10 Day Loss
Revance Therapeutics rank is 491
Negative ROA
Revance Therapeutics rank is 615
Negative ROE
Revance Therapeutics rank is 655
90 Day Loss
Revance Therapeutics rank is 985
Price-to-Book
Revance Therapeutics rank is 1630







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2018 StockSelector.com. All rights reserved.